Skip to main content
Clinical Trials/NCT02327481
NCT02327481
Completed
Not Applicable

Randomized Controlled Trials Comparing Clinical Outcomes of 3D Versus 2D Laparoscopic Surgery for Gastric Cancer

Fujian Medical University0 sites438 target enrollmentJanuary 1, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Stomach Neoplasms
Sponsor
Fujian Medical University
Enrollment
438
Primary Endpoint
Operating time
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The purpose of this study is to explore the feasibility, safety, and efficacy of 3D Laparoscopic Surgery for Gastric Cancer. The patients with gastric adenocarcinoma (cT1-4aN0-3M0) were studied.

Detailed Description

A prospective randomized comparison of 3D and 2D laparoscopic surgery for gastric cancer will be performed, to evaluate the clinical value and provide theoretical basis and clinical experience for the extensive application of the 3D laparoscopic technique. The evaluation parameters are perioperative clinical efficacy, postoperative life quality, immune function and 3-year/5-year survival and recurrence rates.

Registry
clinicaltrials.gov
Start Date
January 1, 2015
End Date
April 26, 2021
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Fujian Medical University
Responsible Party
Principal Investigator
Principal Investigator

Chang-Ming Huang, Prof.

Fujian Medical University Union Hospital

Fujian Medical University

Eligibility Criteria

Inclusion Criteria

  • (1)Age from over 19 to under 74 years
  • (2)cT1-4a(clinical stage tumor), N0-3, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Seventh Edition
  • (3)Heart, lungs, kidneys, and other vital organs function well, with no obvious surgical contraindications
  • (4)Preoperative examination with no distant metastasis, no significantly enlarged lymph nodes around the main abdominal artery, and tumor not a direct violation of the pancreas, spleen, and other surrounding organs
  • (5)American Society of Anesthesiology (ASA) score class I, II, or III
  • (6)Written informed consent

Exclusion Criteria

  • (1)Women during pregnancy or breast-feeding
  • (2)Severe mental disorder
  • (3)History of previous upper abdominal surgery (except laparoscopic cholecystectomy)
  • (4)Enlarged splenic hilar lymph nodes with integration into a mass and surrounding the blood vessels
  • (5)History of unstable angina or myocardial infarction within the past six months
  • (6)History of cerebrovascular accident within the past six months
  • (7)History of continuous systematic administration of corticosteroids within one month
  • (8)History of previous neoadjuvant chemotherapy or radiotherapy
  • (9)T4b tumors
  • (10)Emergency surgery due to complication (bleeding, obstruction, or perforation) caused by gastric cancer

Outcomes

Primary Outcomes

Operating time

Time Frame: 1 day

Operating time

Secondary Outcomes

  • Intraoperative situation(1 day)
  • Postoperative recovery course(10 days)
  • The postoperative pathology(7 days)
  • Inflammatory and immune response(7 days)
  • 5-year overall survival rate(60 months)
  • 3-year disease free survival rate(36 months)
  • Recurrence patterns(60 months)
  • Complication(30 days;36 months)
  • Morbidity and mortality(30 days;36 months)
  • 3-year overall survival rate(36 months)
  • 5-year disease free survival rate(60 months)
  • Hospitalization expenses(1 months)

Similar Trials